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Abstract 
Background: Several clinical trials have shown that immune treatment focus on programmed death-1 and pro-
grammed death-ligand 1 (PD-L1) yields a good clinical efficacy in advanced non-small cell lung cancer (NSCLC). We 
investigated whether the PD-L1 expression was related to clinicopathologic and molecular characteristics in patients 
with surgically resected NSCLC.
Methods: Between December 2008 and 2013, formalin-fixed, paraffin-embedded samples were obtained from 
patients with lung adenocarcinoma at Zhejiang Cancer Hospital. RT-PCR was used to analyze EGFR, KRAS, NRAS, PIK3CA, 
BRAF, HER2 mutations and ALK, ROS1, RET fusion genes. The PD-L1 expression was evaluated by immunohistochemis-
try and staining of 5 % or more was scored as positive expression. Survival analysis was evaluated using the Kaplan–
Meier method. Multivariate regression was performed using the Cox proportional hazards model.
Results: Mutations were detected in 76.6 % of the 385 patients tested: EGFR mutation (n = 205, 53.2 %), followed 
by EML4–ALK rearrangement (n = 18, 4.7 %), KRAS (n = 16, 4.2 %), HER2 (n = 9, 2.3 %), ROS1 rearrangement (n = 8, 
2.1 %), PIK3CA (n = 6, 1.6 %), RET rearrangement (n = 6,1.6 %), BRAF (n = 2, 0.5 %), and NRAS mutations (n = 1, 0.2 %). 
Twenty-four (6.2 %) patients carried coexisting mutations. PD-L1 expression was detected in 48.3 % (186/385) of all 
the patients. PD-L1 positive patients more frequently carried coexisting mutations (18/24, 75 %), followed by single-
gene (145/271, 53.5 %) and pan-negative mutations (23/90, 25.6 %). PD-L1 expression decreased disease-free survival 
(DFS) in univariate analysis (P = 0.014). Multivariate analysis revealed that PD-L1 expression was not an independent 
risk factor for poor DFS and overall survival (OS) (P = 0.22 and 0.37, respectively).
Conclusions: PD-L1 overexpression is more frequently observed in oncogene-mediated lung adenocarcinoma, 
especially with coexisting mutation subtypes. PD-L1 expression is not a prognostic factor in surgically resected lung 
adenocarcinoma patients.
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Background
Lung cancer is the leading cause of cancer-related death 
in China [1]. The standard treatment of lung cancer, 
especially non-small cell lung cancer (NSCLC) comprises 
platinum-based chemotherapy and driver gene-based 
targeted therapy, which resulted in extended survival 
and increased the quality of life in NSCLC patients 
[2–7]. However, drug resistance is a major challenge in 
most patients [8]. The median survival time in advanced 
NSCLC is no more than 2 years because of limited treat-
ments available excluding chemotherapy and targeted 
therapy [9, 10].
Blockade of immune checkpoints in cancer with mono-
clonal antibodies has recently emerged as a promising 
approach to the treatment of solid tumors. Programmed 
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proteins, is a T cell surface receptor that regulates T cell 
activation and proliferation. Its ligand, programmed 
death-ligand 1 (PD-L1), is frequently expressed in many 
types of carcinomas [11–14]. Recent clinical trials found 
that inhibition of the PD-L1-PD1 interaction using spe-
cific antibodies resulted in promising antitumor efficacy in 
patients with various carcinomas [15, 16]. PD-L1 overex-
pression in NSCLC was reported ranging from 19 to 100 % 
[17–19]. Although several studies elucidated the associa-
tion between common driver genes and PD-L1 expression 
in NSCLC, the results remain controversial and the prog-
nostic value of PD-L1 expression is unclear [20].
This study focused on patients with completely 
resected lung adenocarcinoma and evaluated the associa-
tion of PD-L1 expression with clinicopathologic param-




A total of 385 adenocarcinoma patients underwent 
resection between December 2008 and 2013 in Zheji-
ang Cancer Hospital. Histological typing was determined 
according to the 2004 World Health Organization clas-
sification [21]. Tumor-node-metastasis (TNM) staging 
was based on the 7th edition of the lung cancer staging 
system. The recurrence or metastases were confirmed 
using chest CT, brain MRI, and bone scan as well as 
ultrasound and/or CT of the abdomen. The exclusion cri-
teria included: (1) preoperative chemotherapy or radia-
tion therapy, (2) death from other diseases unrelated to 
NSCLC. The Ethics Committee of Zhejiang Cancer Hospi-
tal approved this study and written informed consent was 
obtained from each participant.
Immunohistochemical analysis of PD‑L1 expression
Immunohistochemical (IHC) staining of PD-L1 expres-
sion was performed on 4-6 μm thick formalin-fiated, par-
affi-embedded tissue. The concentration of rabbit primary 
antibody that reacts to PD-L1 The concentration of rab-
bit primary antibody that reacts to PD-L1 (Proteintech 
Group Inc., Chicago, IL, USA, Catalog number: 66248-
1-Ig) was 1:100 in Dako antibody diluent; slides were 
incubated with this antibody overnight at 4 °C. Then, the 
slides were incubated with Ventana Omni Mapanti-rabbit 
secondary antibody for 60 min. AVentana Chromo Map-
Kit was used for antibody detection, and then the slides 
were counterstained with hematoxylin. Next, the slides 
were dehydrated and cover slipped as per normal labo-
ratory protocol. Two independent pathologists (Wei Wu 
and Guoping Cheng) assessed the expressions.
PD-L1 immunostaining results were classified into two 
groups based on the degree and intensity of staining: (1) 
negative, when staining was absent or detected in  <5  % 
of the cells; and (2) positive, when membranous staining 
was present in ≥5 % of the cells.
We used another antibody (5H1, Cell Signaling Tech-
nology, Beverly, MA, USA) to confirmed the PD-L1 
expression in 102 patients. The PD-L1 immunostaining 
criterion is same with the former antibody.
Gene analysis
Genomic DNA or RNA was extracted from tumor tis-
sues according to standard protocols (RNeasy Mini Kit, 
and QiAamp DNA Mini Kit, Qiagen, Hilden, Germany). 
Briefly, the isolated RNA samples were used for reverse 
transcription into cDNA using Revert Aid First Strand 
cDNA Synthesis Kit (Fermentas, St Leon-Rot, Germany). 
Either genomic DNA or cDNA was used for PCR ampli-
fication and sequencing. EGFR, HER2, KRAS, NRAS, 
BRAF, and PIK3CA were PCR amplified using genomic 
DNA. Cycle sequencing of the purified PCR products 
was carried out with PCR primers using the commer-
cially available ADx Mutation Detection Kits (Amory, 
Xiamen, China).
The ALK, ROS1, and RET fusion mRNA was detected 
by PCR with fusion gene detection kit (Amory, Xiamen, 
China). In brief, total RNA was extracted with Qiagen-
RNeasy FFPE Kit. The mRNA was reverse-transcribed to 
cDNA at 42  °C for 1 h. β-actin was used as the internal 
control. The RT-PCR conditions were as follows: an ini-
tial denaturation at 95 °C for 5 min, followed by 95 °C for 
25 s, 64 °C for 20 s, and 72 °C for 20 s to ensure the speci-
ficity; and 31 cycles at 93 °C for 25 s, 60 °C for 35 s, 72 °C 
for 20 s were performed for data collection and sensitiv-
ity analysis. All of the positive genes including mutations 
or fusions were confirmed with Sanger sequencing. All 
the experiments were performed according to the user 
manual as described previously [22].
Statistical analysis
The Chi squared test was used to evaluate the relation-
ships between different driver genes and PD-L1 expres-
sion. Survival curves of pathologically confirmed samples 
were calculated using the Kaplan–Meier method until 
death or last follow-up. Multivariate analysis was per-
formed using the Cox regression model. Statistical analy-
sis was performed with the SPSS 18 software (Chicago, 
IL, USA). P < 0.05 was considered statistically significant. 
The median follow-up was 54  months (6.5–65) and the 
last follow-up date was July 31, 2015.
Results
Patient characteristics
Patients’ clinical profile is presented in Table 1. One hun-
dred and ninety-eight patients (51.4 %) were male with a 
Page 3 of 7Song et al. J Transl Med  (2016) 14:188 
median age of 59 years. One hundred and fifty (39.0 %) 
patients were former or current smokers. Pathologic 
stage I was seen in 121 patients, stage II in 79 patients, 
and stage III in 185 Patients.
Gene analysis results
All the patients were analyzed for EGFR, KRAS, NRAS, 
PIK3CA, BRAF and HER2 mutations and ALK, ROS1, 
RET fusion genes. This analysis included EGFR muta-
tions (n  =  205, 53.2  %), followed by EML4–ALK rear-
rangements (n = 18, 4.7 %), KRAS (n = 16, 4.2 %), HER2 
(n  =  9, 2.3  %), ROS1 (n  =  8, 2.1  %), PIK3CA (n  =  6, 
1.6  %), RET (n  =  6, 1.6  %), BRAF (n  =  2, 0.5  %), and 
NRAS (n = 1, 0.2 %), and 24 coexisting mutations (6.2 %). 
All the nine genes were negative in 90 patients, defined 
as pan-negative. The details of coexisting mutations are 
listed in Table 2.
PD‑L1 expression correlated with driver genes
The PD-L1 membrane expression was detected in 186 of 
the 385 lung adenocarcinoma patients (48.3  %) (Figs.  1, 
2). The relationships between clinical parameters or 
gene characteristics and PD-L1 expression are shown in 
Table  3. PD-L1 expression was not significantly associ-
ated with any clinicopathologic parameters. Patients with 
PD-L1 positive expression more frequently presented 
with coexisting mutations (18/24, 75  %), followed by 
single-gene mutation (145/271, 53.5 %) and pan-negative 
(23/90, 25.6  %) genes. Differences in PD-L1 expression 
were found among the coexisting mutations, single-gene 
mutations and pan-negative genes (P < 0.001).
Another antibody (5H1, Cell Signaling Technology, 
Beverly, MA, USA) was used in 102 patients to detect the 
PD-L1 expression. The same trend of PD-L1 expression 
difference existed in patients with different gene abnor-
mality. The PD-L1 positive patitnets was more frequently 
carried coexisting mutations (5/8, 62.5  %), followed by 
single-gene positive (32/66, 48.5  %) and pan-negative 
mutations (10/28, 25.6 %)(P = 0.337).
Survival analysis
The median DFS and OS were 48.3 and 58.1  months, 
respectively. Patients with positive PD-L1 expression 
had shorter DFS than those with negative PD-L1 expres-
sion (38.0 vs. 50.4 months, P = 0.014) (Fig. 3), but the OS 
between the two groups showed no significant difference 
(52.9 vs. 68.2 months, P = 0.069) (Fig. 4; Table 4).
In univariate analysis, early stage (stage I and II versus 
III) and PD-L1 expression negative were significantly risk 
factors for tumor recurrence or metastasis (Figs.  3, 4), 
while only early stage was a favorable prognostic factor of 
OS (Table 4).
In multivariate analysis, only early stage suggested lower 
risk for DFS, while PD-L1 expression was not correlated 
with recurrence or metastasis. Early stage was an inde-
pendent and favorable prognostic factor for OS (Table 5).
Discussion
This study shows that PD-L1 is overexpressed in 48.3 % 
(186/385) of lung adenocarcinoma patients and this 
overexpression is more frequently seen in patients with 
coexisting mutations, but less frequently in patients with 
pan-negative genes. The PD-L1 overexpression is not a 
prognostic factor for overall survival. To the best of our 
knowledge, this is the first study with the largest number 
of patients correlating the nine common driver genes in 
lung adenocarcinoma and PD-L1 expression.
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Several studies have reported the association between 
PD-L1 expression and driver genes [23, 24]. The results 
of the correlation were controversial. Azuma et  al. [14] 
observed that PD-L1 positive status was significantly 
associated with EGFR mutations . Mu et al. observed no 
significant correlation between PD-L1 expression and 
EGFR/ALK status in stage I NSCLC patients [25]. Simi-
larly, Zhang et al. found that no association between PD-
L1 expression and EGFR status in lung adenocarcinoma 
[25]. Therefore, the role of inhibition of PD-1/PD-L1 
pathway and driver genes based on the results of existing 
studies is inconclusive, due to several reasons. First, most 
of the samples in previous studies were relatively small. 
Second, most of the studies focused on EGFR mutations 
or ALK rearrangements, and other driver genes were not 
well investigated. Last but not least, racial differences 
may play an important role in the controversial results.
In the present study, PD-L1 overexpression was more 
frequent in patients with coexisting mutations than in 
pan-negative patients. One explanation is that the genetic 
differences affected epigenetics, which may alter the 
expression of tumor-associated self-antigens, which in 
turn, affected tumor antigenicity. Increased number of 
driver genes reflects a higher level of neoantigens, which 
alters the immune microenvironment and increases the 
PD-L1 expression [26].
Because of heterogeneity of tumors, the efficacy of 
chemotherapy or molecular targeted treatment is rela-
tively limited, combination treatment with different 
anti-cancer mechanisms drugs hold much potential in 
this area. Previous studies demonstrated that EGFR and 
ALK genes could induce PD-L1 expression to facilitate 
evasion of the host anti-tumour immune response, sug-
gesting an active role for these genes in remodelling the 
immune microenvironment [27, 28]. In this way, combi-
nation of PD-1/PD-L1 blockade with targeted inhibitor 
or other drugs may be a promising therapeutic strategy 
to increase the duration of treatment response and delay 
development of drug resistance.
The role of PD-L1 in predicting the prognosis of 
NSCLC was controversial in previous studies [20]. Some 
studies found that negative PD-L1 expression led to 
superior OS in NSCLC patients compared with positive 
PD-L1 expression [14, 29], while Yang et  al. [30] con-
cluded that PD-L1 expression had no significant cor-
relation with OS. In the present cohort, we found no 
association between the PD-L1 expression and overall 
survival in NSCLC patients. However, PD-L1 expression 
Table 2 Clinical characteristics and PD-L1 expression in concurrent gene alteration patients
Case Gender Age Stage Smoking Gene type PD‑L1 expression OS (month)
1 Male 43 IB Yes EGFR+PIK3CA Yes 67+
2 Female 51 IIIA No RET+PIK3CA Yes 42
3 Female 58 IIIA No EGFR+ALK Yes 34
4 Male 74 IA No EGFR+PIK3CA No 66+
5 Male 60 IIIA Yes KRAS+ALK Yes 35+
6 Female 60 IB No EGFR+RET-M2 Yes 54
7 Female 60 IA No EGFR+PIK3CA Yes 36+
8 Male 64 IIA No RET+PIK3CA No 55
9 Male 69 IB No KRAS6+HER2 Yes 43+
10 Male 45 IIIA Yes KRAS+PIK3CA Yes 25
11 Female 64 IIB Yes EGFR+HER2 No 46+
12 Female 75 IIIA No EGFR+PIK3CA No 24+
13 Female 69 IIA No KRAS+PIK3CA Yes 36
14 Female 49 IB No EGFR+HER2 Yes 48+
15 Female 55 IIB Yes ROS1+HER2 Yes 37+
16 Male 62 IB Yes EGFR+ALK No 46
17 Male 55 IIIA No EGFR+PIK3CA Yes 39
18 Female 68 IB No EGFR+PIK3CA Yes 58+
19 Female 76 IB No ALK+RET-M16 No 28
20 Male 43 IB No EGFR+PIK3CA Yes 55+
21 Male 59 IIIA Yes KRAS+PIK3CA Yes 18+
22 Female 61 IB No EGFR+PIK3CA Yes 66+
23 Female 68 IIA No EGFR+HER2 Yes 45
24 Male 62 IIIA Yes KRAS+HER2 Yes 16
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Fig. 1 a Positive programmed cell death-ligand 1 (PD-L1) immuno-
histochemical staining in a patient with adenocarcinoma. b Negative 
PD-L1 immunohistochemical staining in another patient with 
adenocarcinoma
Fig. 2 Relationship between PD-L1 expression and driver genes
Table 3 Clinical characteristics comparison between PD-L1 
positive and negative expression in NSCLC patients






 Male 87 111
 Female 99 88
Age 0.68
 <60 102 105
 ≥60 84 94
Smoking status 0.12





  I + II 105 95
 III 81 104
EGFR 0.008
 Yes 112 93
 No 74 106
ALK 0.53
 Yes 10 8
 No 176 191
KRAS 0.16
 Yes 5 11
 No 181 188
HER2 0.44
 Yes 6 3
 No 180 196
ROS1 0.65
 Yes 5 3
 No 181 196
PIK3CA 0.74
 Yes 2 4
 No 184 195
RET 0.74
 Yes 3 3
 No 183 196
BRAF 0.45
 Yes 2 0
 No 184 199
NRAS 0.97
 Yes 0 1
 No 186 198
Concurrent alteration 0.01
 Yes 18 6
 No 168 193
Pan-negative <0.01
 Yes 23 67
 No 163 132
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was related to shorter DFS. The results may contribute to 
the treatment after recurrence or metastasis.
Our study limitations are as follows. One major limita-
tion was its retrospective nature. Second, only 24 patients 
with coexisting mutations were included, and the small 
sample size may influence the results of the current study. 
Third, different antibodies were used in different anti-
PD-1 or PD-L1 therapies in clinical trials currently. The 
choice of antibody and the threshold for positivity might 
influence the results of different studies. Only one anti-
body and 5 % threshold were used in the present study. 
Different anti-PD-L1 antibodies may need to be validated 
in the same sample in future studies.
Conclusions
In conclusion, we demonstrated the expression of PD-L1 
in over 48  % of lung adenocarcinoma patients and the 
expression was associated with coexisting driver genes. 
PD-L1 expression is not associated with overall survival 
in patients with completely resected NSCLC.
Abbreviations
PD-1: programmed death-1; NSCLC: non-small cell lung cancer; DFS: disease 
free survival; OS: overall survival.
Fig. 3 Disease free survival curves in patients with positive or 
negative programmed cell death-ligand 1 (PD-L1) staining (38.0 vs. 
50.4 months, P = 0.014)
Fig. 4 Overall survival curves in patients with positive or nega-
tive programmed cell death-ligand 1 (PD-L1) staining (52.9 vs. 
68.2 months, P = 0.069)
Table 4 Univariate analysis for  disease-free survival 
and overall survival
Variables Median DFS P Median OS P
Gender 0.74 0.44
 Male 44.6 55.6
 Female 48.9 59.9
Age 0.23 0.39
 <60 49.3 59.3
 ≥60 42.9 55.2
Smoking status 0.16 0.59
 Never 49.0 58.6
 Former/current 41.3 56.0
Pathologic stage <0.001 <0.001
 I + II 52.5 66.2
 III 30.2 45.0
Adjuvant treatment 0.54 0.76
 Yes 49.7 59.2
 No 46.5 56.5
Driver genes 0.23 0.24
 Positive 48.9 58.7
 Negative 42.0 50.4
PD-L1 expression 0.014 0.069
 Yes 38.0 52.9
 No 50.4 62.0
Table 5 Multivariate survival analysis for disease-free sur-
vival and overall survival
Variables DFS OS
HR 95 % CI P HR 95 % CI P
Smoking status (smok-
ers vs. non-smokers)
0.84 0.66–1.07 0.16 1.12 0.81–1.53 0.48
Stage (III vs. I + II) 1.71 1.32–2.21 0.00 1.16 0.84–1.58 0.00
PD-L1 expression (posi-
tive vs. negative)
1.17 0.91–1.51 0.22 1.79 1.30–2.46 0.37
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